Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Oct
12
Today In Oncology
Insurance and Cost Barriers to Oral Therapies for Blood Cancers
Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
The Wistar Institute Names New President and Chief Executive Officer
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo